Oryzon Genomics, S.A. (Madrid Stock Exchange: ORY, “Oryzon” or the “Company”), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced the successful completion of a capital increase of 5,693,565 new common shares, with gross proceeds of approximately €18.2 million. This represents the maximum capital increase the company could undertake under the current approved resolutions of its General Assembly. The shares were sold at a price of €3.20 per share.
The offering included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe . The majority of the funds were raised from international investors , reinforcing and diversifying the Company’s shareholder base . The Company intends to use the net proceeds from th e capital increase to finance its research and development of clinical pipeline candidates and for working capital and general corporate purposes
"This funding under scores the trust of leading healthcare investors in Oryzon ’s pipeline and particularly in our program for neurodegenerative diseases that will be ready to start Phase 2 later this year . The positive evolution of our clinical trials and this additional funding strengthens the company to further advance the achievement of significant milestones in the development of our drugs ” , commented Carlos Buesa, Oryzon’s CEO.
Guggenheim Securities, LLC and Bryan, Garnier & Co. acted as joint bookrunners for the International tranche . So lventis AV, S.A. , Bankinter, S.A. through Bankinter Securities Sociedad de Valores, S.A. were the coordinators of the Spanish part of the transaction and GVC Gaesco Beka S.V., S.A. acted as p lacement a gent.
Subject to satisfaction of certain customary closing conditions contained in the securities purchase agreements, closing of the transaction including the new shares being admitted to trading on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges, through the Stock Market Interconnection System (Continuous Market) is expected on April 4, 2017.
Oryzon and its directors and executive officers ha ve entered into lock - up agreements ending 90 calendar days after the date hereof , subject to certain customary exceptions.
This announcement does not constitute a prospectus within the meaning of the Prospectus Directive
About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset alread y partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company h as a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic target s through Phase II clinical trials, at which point it is decided on a case - by - case basis to either keep the development in - house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com
cloud technology axon
In February 2024, Business Software Group (BSG) launched a initial pub...
